Promising data on the use of antibody-based regimens in both newly diagnosed and relapsed/refractory multiple myeloma were presented at the 62nd AS......READ MORE
Important new research on cellular and immune-based therapies for relapsed/refractory multiple myeloma was presented at the 62nd ASH Annual Meeting......READ MORE
Patients with multiple myeloma currently have more treatment options than ever before; however, there is still no cure. Researchers at the 62nd ASH......READ MORE
At the 62nd ASH Annual Meeting and Exposition, emerging data were presented relevant to the treatment of frail and/or older patients with multiple ......READ MORE
Patients with multiple myeloma may develop immunoglobulin light chain (AL) amyloidosis during the course of their disease. Several abstracts presen......READ MORE